Arcus Biosciences RCUS
NYSE RCUS
$29.65 -0.48 (-1.59%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arcus Biosciences (RCUS) Operating Income (QoQ) (2017 - 2026)

Analysis

Arcus Biosciences (RCUS) Operating Income (QoQ) (2017 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Arcus Biosciences 3.74 Bn 3.04 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 28.36%
Mar 31, 2026 -17.54%
Dec 31, 2025 19.72%
Sep 30, 2025 -1,675.00%
Jun 30, 2025 93.44%
Mar 31, 2025 -18.45%
Dec 31, 2024 1.90%
Sep 30, 2024 0.94%
Jun 30, 2024 -562.50%
Mar 31, 2024 82.42%
Dec 31, 2023 -13.75%
Sep 30, 2023 3.61%
Jun 30, 2023 3.49%
Mar 31, 2023 -16.22%
Dec 31, 2022 -5.71%
Sep 30, 2022 -1.45%
Jun 30, 2022 -2.99%
Mar 31, 2022 -123.84%
Dec 31, 2021 459.65%
Sep 30, 2021 -2.63%